Study guide
10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
NBCRNA CRNA Certified Registered Nurse Anesthetist NCE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology
1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders
2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms
3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology
4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics
4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics
5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies
5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout
6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators
6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging
7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation
7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways
8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety
8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety
9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation
9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring
10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms
11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)
12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA
12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm
13 Chapter 13: Regional Anesthesia: Neuraxial Blocks
13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma
14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance
14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols
15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice
15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives
16 Chapter 16: Obstetric & Gynecologic Anesthesia
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient
17 Chapter 17: Pediatric Anesthesia
17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm
18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols
19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia
19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction
20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia
20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation
21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology
21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements
22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology
22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices
23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures
23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases
24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control
24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure
25 Chapter 25: Neurosurgical Subspecialty Procedures
25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy
26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia
26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery
27 Chapter 27: Orthopedic & Extremity Anesthesia
27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block
28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy
28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia
29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients
29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient
10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
Key Takeaways Explain This Topic AI
Thromboelastography (TEG) and Rotational Thromboelastometry (ROTEM) provide functional, real-time viscoelastic assessments of whole-blood clot formation, kinetics, dynamic strength, and fibrinolysis at the point of care.
TEG parameters and targeted treatments: Prolonged R-time (reaction time >10 min) reflects coagulation factor deficiency treated with FFP or PCC; prolonged K-time (>3 min) and reduced α-angle (<53°) reflect impaired fibrin polymerization treated with Cryoprecipitate; reduced Maximum Amplitude (MA <50 mm) reflects platelet deficiency/dysfunction (80%) and fibrinogen (20%) treated with Platelets; and elevated LY30 (>3–7.5%) reflects hyperfibrinolysis treated with antifibrinolytics (Tranexamic acid [TXA] or Aminocaproic acid).
ROTEM utilizes dedicated assays (INTEM, EXTEM, FIBTEM, HEPTEM, APTEM) with analogous metrics: Clotting Time (CT = R-time), Clot Formation Time (CFT = K-time), Alpha Angle (α = α-angle), Maximum Clot Firmness (MCF = MA), and Maximum Lysis (ML = LY30); FIBTEM uses cytochalasin D to inhibit platelets, isolating fibrinogen contribution.
Disseminated Intravascular Coagulation (DIC) is an acquired consumptive thrombohemorrhagic disorder characterized by widespread microvascular thrombosis, consumption of clotting factors and platelets, elevated D-dimer/FDPs, marked hypofibrinogenemia, and secondary hyperfibrinolysis.
Heparin-Induced Thrombocytopenia (HIT Type II) is an immune-mediated hypercoagulable state driven by IgG antibodies against Heparin-Platelet Factor 4 (PF4) complexes causing >50% platelet reduction and severe venous/arterial thrombosis; management requires immediate cessation of all heparin products, avoidance of platelet transfusions, and initiation of a non-heparin direct thrombin inhibitor (Argatroban or Bivalirudin).
Last updated: August 2026
10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
Standard plasma coagulation tests (Prothrombin Time [PT/INR], activated Partial Thromboplastin Time [aPTT], and platelet counts) evaluate isolated biochemical components in platelet-poor plasma at static endpoints. They fail to reflect dynamic cellular-protein interactions, platelet function, clot tensile strength, or hyperfibrinolysis, and their 45–60 minute turnaround time limits their utility during active hemorrhage. Viscoelastic point-of-care (POC) testing with Thromboelastography (TEG) and Rotational Thromboelastometry (ROTEM) provides real-time functional assessment of whole-blood clot initiation, propagation, stabilization, and lysis.
1. Principles of Viscoelastic Coagulation Testing
Viscoelastic testing models the cell-based theory of hemostasis (Initiation, Amplification, Propagation, and Fibrinolysis) using whole blood maintained at 37 ∘ C 37^\circ\text{C} 3 7 ∘ C :
TEG Mechanics: Whole blood ( 360 μ L 360\ \mu\text{L} 360 μ L ) is placed in an oscillating cylindrical cup that rotates through an angle of 4.75 ∘ 4.75^\circ 4.7 5 ∘ every 10 seconds. A stationary pin suspended by a torsion wire is lowered into the blood. As fibrin-platelet meshes assemble, torque from the oscillating cup is transmitted to the pin, producing electrical signals that plot amplitude (mm) over time (min).
ROTEM Mechanics: In ROTEM, the cup is stationary while the pin oscillates through 4.75 ∘ 4.75^\circ 4.7 5 ∘ . The optical detection system is less susceptible to external mechanical vibrations and movement artifacts. THE THROMBOELASTOGRAPHY (TEG) TRACING
- <- R ->
- +-----+ <- K ->
- / \+-------+ ---
- / \ \ |
- / α-angle \ \================================== | MA
- ------+-------------+--------+ | (50-70 mm)
- \ / /================================= |
- \ / / |
- \ /+-------+ ---
- +-----+ |
- LY30 (<3%) V
- -------------------------------------------------------------------> Time (min)
- 2. TEG Parameters, Normal Values & Targeted Transfusion Algorithm
TEG Parameter Clinical Definition & Phase Measured Normal Reference Range Underlying Coagulation Defect Targeted First-Line Therapy
R-time (Reaction Time) Time from test initiation until initial fibrin formation ( 2 mm 2\text{ mm} 2 mm amplitude). Reflects the initiation phase of clotting. 5 − 10 minutes 5 - 10\text{ minutes} 5 − 10 minutes Coagulation factor deficiency; presence of anticoagulant (heparin, warfarin, DOACs) Fresh Frozen Plasma ( 10 − 15 mL/kg 10 - 15\text{ mL/kg} 10 − 15 mL/kg ) , 4-Factor PCC, or Protamine (if heparin present)
K-time (Kinetics) Time from R R R ( 2 mm 2\text{ mm} 2 mm ) until clot reaches 20 mm 20\text{ mm} 20 mm amplitude. Reflects clot amplification and kinetics . 1 − 3 minutes 1 - 3\text{ minutes} 1 − 3 minutes Hypofibrinogenemia; impaired fibrin cross-linking; low thrombin generation Cryoprecipitate ( 10 units 10\text{ units} 10 units ) or Fibrinogen Concentrate ( 25 − 50 mg/kg 25 - 50\text{ mg/kg} 25 − 50 mg/kg )
Alpha ( α \alpha α ) Angle Slope of the line drawn from R R R to the curve tangent. Reflects speed of fibrin polymerization and clot growth. 53 ∘ − 72 ∘ 53^\circ - 72^\circ 5 3 ∘ − 7 2 ∘ Hypofibrinogenemia; severe factor deficiency Cryoprecipitate ( 10 units 10\text{ units} 10 units ) or Fibrinogen Concentrate
Maximum Amplitude (MA) Maximum dynamic diameter/width of the tracing. Reflects clot tensile strength ( 80 % 80\% 80% platelet contribution, 20 % 20\% 20% fibrinogen). 50 − 70 mm 50 - 70\text{ mm} 50 − 70 mm Thrombocytopenia; platelet receptor dysfunction (antiplatelet drugs, CPB); severe hypofibrinogenemia Platelets ( 1 apheresis unit 1\text{ apheresis unit} 1 apheresis unit ) ; DDAVP ( 0.3 μ g/kg 0.3\ \mu\text{g/kg} 0.3 μ g/kg ); or Cryoprecipitate if fibrinogen low
LY30 (Lysis at 30 min) Percentage reduction in clot area 30 minutes after reaching MA. Reflects clot stability and fibrinolysis . 0 − 3 % 0 - 3\% 0 − 3% ( < 7.5 % <7.5\% < 7.5% ) Primary or secondary hyperfibrinolysis (excessive tissue plasminogen activator [tPA] activity) Antifibrinolytics: Tranexamic Acid (TXA 1 − 2 g IV 1 - 2\text{ g IV} 1 − 2 g IV ) or Aminocaproic Acid ( 4 − 5 g IV 4 - 5\text{ g IV} 4 − 5 g IV )
G-Value (Shear Modulus) Calculated measure of total clot elasticity ( G = [ 5000 × M A ] / [ 100 − M A ] G = [5000 \times MA] / [100 - MA] G = [ 5000 × M A ] / [ 100 − M A ] ). 5 , 000 − 11 , 000 dyn/cm 2 5,000 - 11,000\text{ dyn/cm}^2 5 , 000 − 11 , 000 dyn/cm 2 Global hypocoagulable state Targeted component therapy based on MA/R
3. ROTEM Assays & Algorithmic Hemostatic Decision-Making
ROTEM utilizes standardized chemical activators and inhibitors to isolate specific pathways within 10–15 minutes. +-------------------------------------------------------------------------+
- | ROTEM ASSAYS & SPECIFIC REAGENTS |
- +---------------------+-----------------------+---------------------------+
- | Assay Name | Activator / Inhibitor | Diagnostic Target |
- +---------------------+-----------------------+---------------------------+
- | INTEM | Ellagic acid (Contact)| Intrinsic pathway (Heparin|
- | EXTEM | Tissue Factor (TF) | Extrinsic pathway (Screen)|
- | FIBTEM | TF + Cytochalasin D | Fibrinogen (Platelets OFF)|
- | HEPTEM | Ellagic acid + Hep'ase| Unmasks Heparin effect |
- | APTEM | TF + Aprotinin/TXA | Confirms Hyperfibrinolysis|
- +---------------------+-----------------------+---------------------------+
- ROTEM Nomenclature vs. TEG Equivalents
Clotting Time (CT): Equivalent to TEG R-time (Normal EXTEM CT: 38 − 79 sec 38 - 79\text{ sec} 38 − 79 sec ). Prolonged CT → \rightarrow → give FFP or PCC .
Clot Formation Time (CFT): Equivalent to TEG K-time (Normal EXTEM CFT: 34 − 159 sec 34 - 159\text{ sec} 34 − 159 sec ). Prolonged CFT → \rightarrow → give Cryoprecipitate .
Alpha Angle ( α \alpha α ): Equivalent to TEG α \alpha α -angle (Normal EXTEM α \alpha α : 63 − 83 ∘ 63 - 83^\circ 63 − 8 3 ∘ ). Reduced α \alpha α → \rightarrow → give Cryoprecipitate .
Maximum Clot Firmness (MCF): Equivalent to TEG MA (Normal EXTEM MCF: 50 − 72 mm 50 - 72\text{ mm} 50 − 72 mm ). Reduced MCF → \rightarrow → evaluate FIBTEM.
Maximum Lysis (ML): Equivalent to TEG LY30 (Normal EXTEM ML: < 15 % <15\% < 15% ). Elevated ML ( > 15 % >15\% > 15% ) → \rightarrow → give TXA .
The FIBTEM Differential (Critical Clinical Strategy)
In a bleeding patient with a low EXTEM clot strength ( M C F < 50 mm MCF < 50\text{ mm} MCF < 50 mm ):
Check FIBTEM MCF: FIBTEM contains cytochalasin D , a fungal alkaloid that depolymerizes platelet actin filaments, completely paralyzing platelet contraction and isolating the pure fibrinogen contribution to clot firmness.
If FIBTEM MCF is LOW ( < 9 − 10 mm <9 - 10\text{ mm} < 9 − 10 mm ): The coagulopathy is driven by hypofibrinogenemia → \rightarrow → administer Cryoprecipitate (10 units) or Fibrinogen Concentrate.
If FIBTEM MCF is NORMAL ( > 10 − 12 mm >10 - 12\text{ mm} > 10 − 12 mm ) while EXTEM MCF is LOW ( < 45 mm <45\text{ mm} < 45 mm ): Fibrinogen is adequate; the defect is pure thrombocytopenia or platelet dysfunction → \rightarrow → administer Platelets (1 apheresis unit) .
The HEPTEM Differential (Heparin Reversal)
INTEM CT is prolonged , but HEPTEM CT (which contains heparinase) is NORMAL: Confirms residual heparin effect → \rightarrow → administer Protamine Sulfate .
If both INTEM CT and HEPTEM CT are prolonged → \rightarrow → true clotting factor deficiency → \rightarrow → administer FFP or 4F-PCC .
4. Disseminated Intravascular Coagulation (DIC)
Disseminated Intravascular Coagulation is an acquired, life-threatening consumptive thrombohemorrhagic syndrome characterized by systemic intravascular activation of coagulation cascades. +-------------------------------------------------------------------------+
- | PATHOPHYSIOLOGIC CASCADE OF DIC |
- +-------------------------------------------------------------------------+
- | Massive Tissue Factor (TF) Exposure / Endothelial Injury / Cytokines |
- | │ |
- | ▼ |
- | Uncontrolled Thrombin Generation & Microvascular Fibrin Deposition |
- | ├──────────────────────────────────┼──────────────────────────────────┤
- | ▼ ▼ ▼
- | Microvascular Thrombosis Consumption of Factors & Secondary Hyper-
- | & Multiorgan Dysfunction Platelets (Exhaustion) fibrinolysis (tPA)
- | (Ischemia, AKI, ARDS) (Thrombocytopenia/Low Fibrin) (FDPs / D-Dimer)
- | │ │
- | └─────────────────┬────────────────┘
- | ▼
- | SEVERE SYSTEMIC HEMORRHAGE
- +-------------------------------------------------------------------------+
- Etiologies & Triggering Mechanisms
Obstetric Catastrophes: Amniotic Fluid Embolism (AFE) (amniotic fluid contains abundant tissue factor and procoagulant mucin), Placental Abruption (decidual tissue factor entry into maternal circulation), retained dead fetus, and severe HELLP syndrome.
Severe Trauma & Burns: Massive tissue necrosis, crush injuries, fat embolism, and traumatic brain injury (brain parenchyma has the highest concentration of tissue factor in the human body).
Severe Sepsis & Septic Shock: Gram-negative lipopolysaccharide (LPS / endotoxin) and inflammatory cytokines (TNF- α \alpha α , IL-1, IL-6) induce monocyte tissue factor expression, downregulate thrombomodulin, and consume protein C.
Malignancy: Acute promyelocytic leukemia (APL) and mucin-secreting adenocarcinomas.
- ABO Incompatible Hemolytic Transfusion Reactions
- Diagnostic Laboratory Profile in Overt DIC
Platelet Count: Severely decreased ( < 50 , 000 − 100 , 000 / μ L <50,000 - 100,000/\mu\text{L} < 50 , 000 − 100 , 000/ μ L ) due to widespread consumption.
Fibrinogen: Markedly depressed ( < 100 − 150 mg/dL <100 - 150\text{ mg/dL} < 100 − 150 mg/dL ); profound depletion is a hallmark of severe decompensated DIC.
PT / INR & aPTT: Markedly prolonged due to global clotting factor exhaustion.
D-Dimer & Fibrin Degradation Products (FDPs): Markedly elevated (reflecting secondary plasmin degradation of cross-linked fibrin clots).
Peripheral Blood Smear: Schistocytes (helmet cells / fragmented red blood cells) resulting from microangiopathic shearing across microvascular fibrin strands.
Anesthetic & Resuscitative Management of DIC
Etiologic Treatment: Definitive management requires immediate eradication of the underlying trigger (e.g., immediate emergent delivery of the fetus and placenta in abruption/AFE; surgical debridement of necrotic tissue; broad-spectrum antibiotics and source control in sepsis).
Goal-Directed Transfusion Support:
Cryoprecipitate: Transfuse 10-unit pools to maintain fibrinogen > 150 − 200 mg/dL >150 - 200\text{ mg/dL} > 150 − 200 mg/dL .
Platelets: Transfuse apheresis units to maintain platelets > 50 , 000 / μ L >50,000/\mu\text{L} > 50 , 000/ μ L (or > 100 , 000 / μ L >100,000/\mu\text{L} > 100 , 000/ μ L with severe bleeding).
FFP: Transfuse 10 − 15 mL/kg 10 - 15\text{ mL/kg} 10 − 15 mL/kg to keep INR < 1.5 <1.5 < 1.5 and correct global factor deficiencies.
Antifibrinolytic Precaution: Tranexamic acid (TXA) and aminocaproic acid are generally contraindicated in classic overt DIC because blocking fibrinolysis in the presence of ongoing systemic thrombin generation promotes uninhibited microvascular thrombosis, diffuse tissue infarction, and cortical renal necrosis (exception: documented primary hyperfibrinolytic state or severe trauma with TEG LY30 > 7.5 % >7.5\% > 7.5% ).
5. Heparin-Induced Thrombocytopenia (HIT Type II)
Heparin-Induced Thrombocytopenia is an immune-mediated, life-threatening prothrombotic disorder triggered by exposure to unfractionated heparin (UFH) or, less commonly, low-molecular-weight heparin (LMWH). +-------------------------------------------------------------------------+
- | HIT TYPE II IMMUNOPATHOGENESIS |
- +-------------------------------------------------------------------------+
- | Unfractionated Heparin (UFH) binds Platelet Factor 4 (PF4) |
- | │ |
- | ▼ |
- | Formation of Immunogenic Heparin-PF4 Macromolecular Complexes |
- | │ |
- | ▼ |
- | Patient synthesizes IgG Autoantibodies against Heparin-PF4 |
- | │ |
- | ▼ |
- | IgG-Heparin-PF4 Complexes crosslink Platelet FcgRIIa Receptors |
- | │ |
- | ▼ |
- | Massive Platelet Activation, Procoagulant Microparticle Release |
- | ├──────────────────────────────────┴──────────────────────────────────┤
- | ▼ ▼
- | Consumption of Platelets (>50% drop) PARADOXICAL THROMBOSIS
- | (White Clot Syndrome)
- | - Venous: DVT, PE
- | - Arterial: Stroke, MI, Limb
- +-------------------------------------------------------------------------+
- HIT Type I vs. HIT Type II Comparison
Feature HIT Type I (Non-Immune) HIT Type II (Immune-Mediated)
Pathophysiology Direct non-immune platelet agglutination by heparin IgG antibody against Heparin-PF4 complexes activating F c γ RIIa Fc\gamma\text{RIIa} F c γ RIIa
Onset Timing Early ( 1 − 2 days 1 - 2\text{ days} 1 − 2 days of heparin exposure) 5 − 10 days 5 - 10\text{ days} 5 − 10 days ( < 24 hours <24\text{ hours} < 24 hours if prior heparin within 90 days)
Platelet Nadir Mild ( > 100 , 000 / μ L >100,000/\mu\text{L} > 100 , 000/ μ L ); rarely < 100 k <100\text{k} < 100 k Severe: > 50 % >50\% > 50% drop from baseline (even if absolute count > 100 k >100\text{k} > 100 k )
- Thrombosis Risk None (benign) Extremely High ( 30 − 50 % 30 - 50\% 30 − 50% ) (venous and arterial thrombosis)
- Heparin Therapy Can be safely continued MUST BE STOPPED IMMEDIATELY
Morbidity / Mortality Negligible High mortality ( 20 − 30 % 20 - 30\% 20 − 30% ), limb loss, pulmonary embolism
The 4T Clinical Scoring System
T - Thrombocytopenia: > 50 % >50\% > 50% drop in platelets with nadir ≥ 20 , 000 / μ L \ge 20,000/\mu\text{L} ≥ 20 , 000/ μ L (2 pts); 30 − 50 % 30-50\% 30 − 50% drop (1 pt); < 30 % <30\% < 30% drop (0 pts).
T - Timing of Platelet Fall: Onset between Days 5–10, or ≤ 1 day \le 1\text{ day} ≤ 1 day with heparin exposure in past 30 days (2 pts); onset after Day 10 or Day 1 with exposure 30–100 days ago (1 pt); onset < 4 days <4\text{ days} < 4 days without recent exposure (0 pts).
T - Thrombosis: Proven new thrombosis, skin necrosis at injection site, or acute systemic reaction after IV bolus (2 pts); progressive/recurrent thrombosis or silent DVT (1 pt); none (0 pts).
T - oTher Causes Excluded: No other cause apparent (2 pts); possible alternative cause (1 pt); definite alternative cause (0 pts).
Scoring: 6 − 8 points 6 - 8\text{ points} 6 − 8 points = High Probability ; 4 − 5 points 4 - 5\text{ points} 4 − 5 points = Intermediate; ≤ 3 points \le 3\text{ points} ≤ 3 points = Low Probability.
Definitive Management of HIT Type II
DISCONTINUE ALL HEPARIN IMMEDIATELY: Stop all therapeutic and prophylactic heparin, LMWH, heparin flushes, heparin-coated central lines, and dialysis catheters.
DO NOT TRANSFUSE PLATELETS: Platelet transfusions are strictly contraindicated in HIT Type II because transfused platelets provide fresh substrate and F c γ RIIa Fc\gamma\text{RIIa} F c γ RIIa receptors for antibody-mediated activation, precipitating catastrophic arterial thrombosis ("fueling the fire"). Transfuse platelets only for life-threatening intracranial hemorrhage.
Initiate Alternative Non-Heparin Anticoagulation: Because HIT is a hypercoagulable state with a 30 − 50 % 30-50\% 30 − 50% risk of thrombosis, stopping heparin alone is insufficient; active alternative anticoagulation must be started immediately:
Argatroban (Direct Thrombin Inhibitor): Small-molecule univalent direct thrombin inhibitor. Metabolized and cleared by the LIVER (hepatic clearance) . Drug of choice in patients with renal failure or renal insufficiency . Monitored using aPTT (target 1.5 − 3.0 × 1.5 - 3.0\times 1.5 − 3.0 × baseline).
Bivalirudin (Direct Thrombin Inhibitor): Synthetic bivalent direct thrombin inhibitor. Enzymatically degraded in plasma ( 80 % 80\% 80% ) and renally cleared ( 20 % 20\% 20% ) . Drug of choice for cardiac surgery requiring cardiopulmonary bypass (CPB) and in patients with severe hepatic failure .
Fondaparinux (Factor Xa Inhibitor): Synthetic pentasaccharide; renally cleared.
Warfarin Warning: Do NOT start warfarin until the platelet count has fully recovered to baseline or > 150 , 000 / μ L >150,000/\mu\text{L} > 150 , 000/ μ L and the patient is therapeutic on a direct thrombin inhibitor. Starting warfarin during acute HIT precipitates rapid depletion of Protein C (short t 1 / 2 = 6 hours t_{1/2} = 6\text{ hours} t 1/2 = 6 hours ) before factor II/X are suppressed, creating an uninhibited procoagulant state that triggers warfarin-induced skin necrosis and venous limb gangrene .